注射用特利加压素的安全性分析

doi:10.19803/j.1672-8629.2022.06.15

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (6): 654-656.
DOI: 10.19803/j.1672-8629.2022.06.15

注射用特利加压素的安全性分析

李晓菲¹, 程蓉², 吴雪梅³, 刘智^1,*

¹贵州医科大学附属医院药剂科,贵州贵阳 550001;
²贵州省药品评价中心,贵州贵阳 550081;
³贵州医科大学附属医院医学网络中心,贵州贵阳 550001

收稿日期:2020-07-22 出版日期:2022-06-15 发布日期:2022-06-13
通讯作者: ^* 刘智,男,教授,主任药师,药品不良反应监测。E-mail：liuzhigy@163.com
作者简介:李晓菲,女,硕士,主管药师,临床药学。

Safety of terlipressin for injection based on electronic medical records

LI Xiaofei¹, CHENG Rong², WU Xuemei³, LIU Zhi^1,*

¹Department of Pharmacy, the Affiliated Hospital of Guizhou Medical University, Guiyang Guizhou 550001, China;
²Guizhou Provincial Center for Drug Reevaluation, Guiyang Guizhou 550081, China;
³Medical Network Center, the Affiliated Hospital of Guizhou Medical University, Guiyang Guizhou 550001, China

Received:2020-07-22 Online:2022-06-15 Published:2022-06-13

摘要/Abstract

摘要： 目的了解特利加压素药品不良反应（ADR）发生率及临床表现,为临床安全用药提供参考。方法收集某院2016年1月1日至2019年12月31日使用特利加压素患者的电子诊疗病历及ADR报告。按照患者性别、年龄、累及系统-器官、临床表现、转归等情况进行统计分析。结果共收集到1 816例使用特利加压素患者病历,ADR报告56份,发生率为3.08%,女性ADR发生率高于男性,45岁以上不良反应发生率最高。ADR主要累及消化系统、心血管系统,主要表现为腹泻、腹痛、心悸、胸闷等。结论特利加压素所致ADR发生率为常见范畴,临床表现多样,应用需提高警惕,加强用药监护,避免严重发生,保证用药安全。

关键词: 特利加压素, 药品不良反应, 安全性, 合理用药

Abstract: Objective To investigate the incidence of adverse drug reactions (ADR) and clinical symptoms related to terlipressin. Methods The electronic medical records and ADR reports of patients using terlipressin in the Affiliated Hospital of Guizhou Medical University between 2016 to 2019 were collected. Statistical analysis was conducted according to patients' gender, age, clinical manifestations and outcomes. Results A total of 1 816 medical records and 56 ADR reports of patients using terlipressin were collected. The incidence of ADR was 3.08%, and higher among females than among males. Males over 45 years old were the most vulnerable. Adverse reactions mainly involved the digestive system and cardiovascular system, manifested as diarrhea, abdominal pain and palpitations. Conclusion The clinical manifestations of terlipressin-induced adverse drug reactions vary. To prevent serious ADR and ensure drug safety, clinicians should be vigilant and drug monitoring needs to be strengthened.

Key words: terlipressin, adverse drug reactions, safety analysis, rational drug use

中图分类号:

R994.11

李晓菲, 程蓉, 吴雪梅, 刘智. 注射用特利加压素的安全性分析[J]. 中国药物警戒, 2022, 19(6): 654-656.

LI Xiaofei, CHENG Rong, WU Xuemei, LIU Zhi. Safety of terlipressin for injection based on electronic medical records[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 654-656.

参考文献

[1] GARCIA-TSAO G, SANYAL AJ, GRACE ND, et al.Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis[J]. Hepatology, 2007, 46(3): 922-938
[2] WANG DY.Srudy on definition and scope of adverse drug reaction surveillance[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(12): 732-738.
[3] TIEU C, BREDER CD.A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries[J]. Drug Saf, 2018, 41(12): 1375-1385.
[4] CHENG JJ, WANG Z.Grading criteria for severity of adverse drug reaction damage and its bibliometric analysis[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2019, 19(4): 487-490.
[5] LI J, DU H.Epidemiological analysis of patients with liver disease admitted in infectious diseases department of Tangdu Hospital from 2013 to 2019[J]. Clinical Research and Practice(临床医学研究与实践), 2020, 5(10): 1-2, 5.
[6] MOKDAD AA, LOPEZ AD, SHAHRAZ S, et al.Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis[J]. BMC Med, 2014, 12: 145.
[7] NEVENS F, BITTENCOURT PL, COENRAAD MJ, et al.Recomm-endations on the diagnosis and initial management of acute variceal bleeding and hepatorenal syndrome in patients with cirrhosis[J]. Dig Dis Sci, 2019, 64(6): 1419-1431.
[8] KRAG A, BORUP T, MØLLER S, et al. Efficacy and safety of terlipr-essin in cirrhotic patients with variceal bleeding or hepatorenal syndrome[J]. Adv Ther, 2008, 25(11): 1105-1140.
[9] CAVALLIN M, PIANO S, ROMANO A, et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology, 2016, 63(3): 983-992.
[10] GERBES AL, HUBER E, GÜLBERG V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration[J]. Gastroenterology, 2009, 137(3): 1179.
[11] CAVALLIN M, FASOLATO S, MARENCO S, et al.The treatment of hepatorenal syndrome[J]. Dig Dis, 2015, 33(4): 548-554.
[12] GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Terlipr-essin for hepatorenal syndrome[J]. Cochrane Database Syst Rev, 2012(9): CD005162.
[13] OZEL COSKUN BD, KARAMAN A, GORKEM H, et al.Terlipressin-induced ischemic skin necrosis: a rare association[J]. Am J Case Rep, 2014, 15: 476-479
[14] KIM HR, LEE YS, YIM HJ, et al.Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome[J]. Clin Mol Hepatol, 2013, 19(4): 417-420.
[15] ŠÍMA M, POKORNÝ M, PAĎOUR F, et al. Terlipressin induced severe hyponatremia[J]. Prague Med Rep, 2016,117(1): 68-72.

注射用特利加压素的安全性分析

Safety of terlipressin for injection based on electronic medical records

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾茵茵, 张财树, 周颖, 刘丽, 耿颖, 魏宁漪, 钮思静, 陈华, 许卉. 吸入制剂微细粒子空气动力学粒径分布评价方法研究[J]. 中国药物警戒, 2024, 21(2): 141-146.
[2]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[3]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[4]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[5]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[6]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[7]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[8]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[9]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[10]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[11]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[12]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[13]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[14]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[15]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.